| scholarly article | Q13442814 |
| P50 | author | Mark Issa | Q83187469 |
| Muriel Cuendet | Q88042053 | ||
| P2093 | author name string | A A L Gunatilaka | |
| E M K Wijeratne | |||
| P2860 | cites work | Characterization of clonogenic multiple myeloma cells | Q24610291 |
| Roots of Withania somnifera Inhibit Forestomach and Skin Carcinogenesis in Mice | Q24795305 | ||
| Multiple myeloma cancer stem cells | Q26752365 | ||
| Withaferin-A--A Natural Anticancer Agent with Pleitropic Mechanisms of Action | Q26766956 | ||
| Cancer stem cells are the cause of drug resistance in multiple myeloma: fact or fiction? | Q26785497 | ||
| Primer3--new capabilities and interfaces | Q29614816 | ||
| Mechanisms of cancer drug resistance | Q29615849 | ||
| EMT, cancer stem cells and drug resistance: an emerging axis of evil in the war on cancer | Q29616360 | ||
| Tumour stem cells and drug resistance | Q29617742 | ||
| Scientific basis for the therapeutic use of Withania somnifera (ashwagandha): a review | Q34012693 | ||
| Retracted: Bak Compensated for Bax in p53-null Cells to Release Cytochrome c for the Initiation of Mitochondrial Signaling during Withanolide D-Induced Apoptosis | Q34222357 | ||
| Steroidal lactones from Withania somnifera, an ancient plant for novel medicine | Q34994211 | ||
| The interaction of bortezomib with multidrug transporters: implications for therapeutic applications in advanced multiple myeloma and other neoplasias | Q35552693 | ||
| Multiple myeloma cancer stem cells | Q37029171 | ||
| Bruceantin inhibits multiple myeloma cancer stem cell proliferation | Q37283018 | ||
| Silencing NOTCH signaling causes growth arrest in both breast cancer stem cells and breast cancer cells | Q37323067 | ||
| The search for multiple myeloma stem cells: the long and winding road | Q37628876 | ||
| Multiple myeloma: a paradigm for translation of the cancer stem cell hypothesis | Q37698645 | ||
| Normal stem cells and cancer stem cells: similar and different | Q37740620 | ||
| Natural products: promising resources for cancer drug discovery | Q37894788 | ||
| Investigational ABC transporter inhibitors | Q38001734 | ||
| Epigenetic alterations involved in cancer stem cell reprogramming | Q38058972 | ||
| The role of aldehyde dehydrogenase (ALDH) in cancer drug resistance. | Q38110652 | ||
| Myeloma stem cell concepts, heterogeneity and plasticity of multiple myeloma. | Q38151195 | ||
| Fact or fiction--identifying the elusive multiple myeloma stem cell | Q38169258 | ||
| The role of P-glycoprotein in drug resistance in multiple myeloma | Q38200143 | ||
| Withanolide D induces apoptosis in leukemia by targeting the activation of neutral sphingomyelinase-ceramide cascade mediated by synergistic activation of c-Jun N-terminal kinase and p38 mitogen-activated protein kinase. | Q39656557 | ||
| 2,3-Dihydrowithaferin A-3beta-O-sulfate, a new potential prodrug of withaferin A from aeroponically grown Withania somnifera | Q39908922 | ||
| Enhancements and modifications of primer design program Primer3. | Q40230955 | ||
| Antifungal and cytotoxic activity of withanolides from Acnistus arborescens | Q42999718 | ||
| Withania somnifera root extract prevents DMBA-induced squamous cell carcinoma of skin in Swiss albino mice | Q44139253 | ||
| Cancer stem cells: an evolving concept | Q83213559 | ||
| Treatment of multiple myeloma | Q83975326 | ||
| Cancer stem cells: the challenges ahead | Q86523719 | ||
| Withaferin A induces cell death and differentiation in multiple myeloma cancer stem cells | Q90949069 | ||
| P921 | main subject | multiple drug resistance | Q643839 |
| P304 | page(s) | 610 | |
| P577 | publication date | 2017-09-08 | |
| P1433 | published in | Frontiers in Pharmacology | Q2681208 |
| P1476 | title | Withanolide D Exhibits Similar Cytostatic Effect in Drug-Resistant and Drug-Sensitive Multiple Myeloma Cells | |
| P478 | volume | 8 |
Search more.